Norharmane

Norharmane

SCHEMBL21378153

[H+].[H+].[H+].[H+].c1ccc2c(c1)[nH]c1cnccc12

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHUK O15111 7/20 0.96
GABRA1 P14867 2/20 0.96
GABRG2 P18507 2/20 0.96
GABRB3 P28472 2/20 0.96
GABRA5 P31644 2/20 0.96
GABRA3 P34903 2/20 0.96
GABRA2 P47869 2/20 0.96
ALDH1A1 P00352 2/20 0.96
KDM4E B2RXH2 1/20 0.96
GABRP O00591 1/20 0.96
GABRD O14764 1/20 0.96
IKBKB O14920 1/20 0.96
AURKA O14965 1/20 0.96
PIM1 P11309 1/20 0.96
TOP1 P11387 1/20 0.96
IDO1 P14902 1/20 0.96
HPGD P15428 1/20 0.96
GABRB1 P18505 1/20 0.96
MAOA P21397 1/20 0.96
MAOB P27338 1/20 0.96

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Norharmane SCHEMBL28243496 1.00 CHUK (0.96) CHUKGABRA1GABRG2GABRB3GABRA5
Norharmane SCHEMBL9486853 0.98 CHUK (1.00) CHUKGABRA1GABRG2GABRB3GABRA5
Norharmane SCHEMBL29370219 0.98 CHUK (1.00) CHUKGABRA1GABRG2GABRB3GABRA5
Carbazole SCHEMBL18684843 0.98 CHUK (1.00) CHUKGABRA1GABRG2GABRB3GABRA5
Norharmane SCHEMBL25834 0.98 CHUK (1.00) CHUKGABRA1GABRG2GABRB3GABRA5
Norharmane SCHEMBL11561251 0.96 CHUK (0.96) CHUKGABRA1GABRG2GABRB3GABRA5
Norharmane SCHEMBL8686167 0.96 CHUK (0.96) CHUKGABRA1GABRG2GABRB3GABRA5
Norharmane SCHEMBL8683826 0.96 CHUK (0.96) CHUKGABRA1GABRG2GABRB3GABRA5
Norharmane SCHEMBL29809643 0.96 CHUK (0.96) CHUKGABRA1GABRG2GABRB3GABRA5
Norharmane SCHEMBL28902872 0.96 CHUK (0.96) CHUKGABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10829491-B2 Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD (CN) 2020-11-10 US claimed
EP-3546460-B1 PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2020-07-08 EP claimed
EP-3546460-A1 PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2019-10-02 EP claimed
US-20190292183-A1 PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2019-09-26 US claimed
US-10829491-B2 Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD (CN) 2020-11-10 US disclosed
EP-3546460-B1 PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2020-07-08 EP disclosed
EP-3546460-A1 PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2019-10-02 EP disclosed
US-20190292183-A1 PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292183-A1 PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF BTK, SYK, CDK8 CHUK 264/4885GABRA1 2346/4885GABRG2 2107/4885
US-10829491-B2 Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof BTK, SYK, CDK8 CHUK 264/4885GABRA1 2346/4885GABRG2 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.